Senseonics Holdings (NYSE: SENS) reported Q4 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $8 million versus the consensus estimate of $7.5 million.

First Half 2024 Financial Outlook:

Senseonics expects first half of 2024 global net revenue to be nearly $10 million, representing growth of approximately 16% compared to the first half of 2023. Senseonics plans to provide its full year 2024 financial outlook in the second quarter following a comprehensive analysis of the current commercial dynamics by the new leadership at the Ascensia Diabetes Care CGM business unit and an updated view on product approval and launch timing and expectations.

For earnings history and earnings-related data on Senseonics Holdings (SENS) click here.